In conclusion, PDTC in our series homogeneously classified by the Turin consensus were genomically clustered into NRAS-mutated tumors (with low mutational burden and co-mutations affecting genes involved in the same pathway), TP53-mutated cancers (with high mutational burden, absence of TERTp mutations, strong association with MMR defects, and predominant oncocytic features), and a third heterogeneous group of non-NRAS/non-TP53 mutated cases. Here, TP53 is linked to cancer.